BIT Capital GmbH Acquires Shares of 115,697 COMPASS Pathways plc (NASDAQ:CMPS)

BIT Capital GmbH acquired a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 115,697 shares of the company's stock, valued at approximately $437,000. BIT Capital GmbH owned approximately 0.17% of COMPASS Pathways at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. EntryPoint Capital LLC boosted its holdings in shares of COMPASS Pathways by 55.2% during the fourth quarter. EntryPoint Capital LLC now owns 65,519 shares of the company's stock worth $248,000 after purchasing an additional 23,311 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in COMPASS Pathways in the 4th quarter worth about $54,000. Brown University grew its holdings in COMPASS Pathways by 194.6% in the 4th quarter. Brown University now owns 214,200 shares of the company's stock valued at $810,000 after buying an additional 141,500 shares during the period. Essential Planning LLC. acquired a new position in shares of COMPASS Pathways during the 4th quarter valued at about $70,000. Finally, Wealthfront Advisers LLC purchased a new position in shares of COMPASS Pathways during the 4th quarter worth about $43,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Canaccord Genuity Group dropped their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective for the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $18.00 target price on shares of COMPASS Pathways in a research report on Wednesday, January 15th. HC Wainwright reiterated a "buy" rating and set a $45.00 target price on shares of COMPASS Pathways in a report on Tuesday, March 4th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of COMPASS Pathways in a report on Friday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways presently has a consensus rating of "Buy" and a consensus price target of $21.83.

Remove Ads

COMPASS Pathways Stock Down 2.5 %

CMPS traded down $0.07 on Monday, reaching $2.87. The company's stock had a trading volume of 577,181 shares, compared to its average volume of 1,187,839. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 1 year low of $2.72 and a 1 year high of $10.31. The business's 50 day moving average is $3.86 and its 200 day moving average is $4.70. The stock has a market cap of $265.60 million, a price-to-earnings ratio of -1.30 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). As a group, research analysts forecast that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.